Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Comorbidities associated with Egyptian diabetic foot disease subtypes

The Egyptian Journal of Internal Medicine volume 25, pages 154–158 (2013)Cite this article

Abstract

Introduction

Diabetic foot problems are highly prevalent, responsible for almost 50% of all diabetes-related hospital admissions and a 10-year reduction in life expectancy. The main factors involved in the pathology of diabetic foot are neuropathy, ischemia, and infection. The comorbidities of diabetes are hypertension, obesity, and dyslipidemia. Because of the huge premature morbidity and mortality associated with diabetes, prevention of complications is a key issue and, therefore, it is essential to understand the basic mechanisms that lead to tissue damage.

Aim of the work

The aim of our study was to detect the association between patient comorbidities, chronic complications, and different diabetic foot types for the early detection and management of these conditions.

Patients

We carried out a cross-sectional study of 80 consecutive outpatient Egyptian patients with diabetic foot disease in the National Institute of Diabetes and Endocrinology.

Results

Sixty-three percent were purely neuropathic, followed by 19% that were neuroischemic, whereas 18% were of the ischemic type. Hypertension is the most common comorbid condition and coronary artery disease is highly prevalent in the ischemic and neuroischemic types. The coexistence of hypercholesterolemia, smoking, diabetes, and male sex appears to significantly increase the incidence of ischemic diabetic foot. Nephropathy and retinopathy are significantly associated with neuropathic foot ulcers. Hypertriglyceridemia correlates positively to ischemic and neuroischemic ulcers whereas low HDL and proteinuria correlate positively to both neuropathic and neuroischemic ulcers.

Conclusion

Special attention should be paid toward the identification of patients who are at risk of foot ulceration to help prevent foot problems. Comorbid conditions must also be identified early and managed aggressively.

References

  1. Boulton AJ, Meneses P, Ennis WJ. Diabetic foot ulcers: a framework for prevention and care. Wound Repair Regen 1999; 7: 7–16.

    Article  CAS  Google Scholar 

  2. Doupis J, Grigoropoulou P, Voulgari C, Stylianou A, Georga A, Thomakos P, et al. High rates of comorbid conditions in patients with type 2 diabetes and foot ulcers. Wounds 2008; 20: 132–138.

    Google Scholar 

  3. Williams LH, Rutter CM, Katon WJ. Medical comorbids and risk factors and incident diabetic foot ulcers: a prospective cohort study. Am J Med 2010; 123: 748–764.

    Article  PubMed  Google Scholar 

  4. Klenerman L, Wood B. The human foot: a companion to medical studies. London: Springer–Verlag; 2006.

  5. Lavrey LA, Armstrong DG, Harkless LB. The natural history of great toe amputations. J Foot Ankle Surg 1996; 35: 528–531.

    Article  Google Scholar 

  6. Gershater MA, Löndahl M, Nyberg P, Larsson J, Thörne J, Eneroth M, et al. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. Diabetologia 2009; 52: 398–407.

    Article  CAS  Google Scholar 

  7. Inlow S, Orsted H, Sibbald RG. Best practices for the prevention, diagnosis and treatment of diabetic foot ulcers. Ostomy Wound Manage 2000; 46: 55–68, quiz 70–71.

    Google Scholar 

  8. Selby JV, Zhang D. Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 1995; 18: 509–516.

    Article  CAS  Google Scholar 

  9. Mantey I, Foster AVM, Spencer S, Edmonds ME, Edmonds M. Why do foot ulcers recur in diabetic patients? Diabet Med 1999; 16: 245–249.

    Article  CAS  Google Scholar 

  10. Edmonds ME, Foster AVM. Diabetic foot ulcers. Br Med J 2006; 332: 407–410.

    Article  Google Scholar 

  11. Yoshida H, Hirowatari Y, Kurosawa H, Manita D, Yanai H, Ito K, et al. Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels. Atherosclerosis 2012; 222: 541–544.

    Article  CAS  Google Scholar 

  12. Tseng KH, Poulter NR, Sever PS, Dahlöf B, Wedel H. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOTLLA). Diabetes Care 2005; 28: 2595–2596.

    Article  Google Scholar 

  13. Laakso M, Pyorala K. Lipid and lipoprotein abnormalities in diabetic patients with peripheral vascular disease. Atherosclerosis 1988; 74: 55–63.

    Article  CAS  Google Scholar 

  14. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis AN, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE multicentre study. Curr Med Res Opin 2004; 20: 1691–1701.

    Article  Google Scholar 

  15. Hooi JD, Kester ADM, HEJHStoffers, Overdijk MM, VanRee JW, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001; 153: 666–672.

    Article  CAS  Google Scholar 

  16. Eguchi K. Ambulatory blood pressure monitoring in diabetes and obesity - A review. Int J Hypertens 2011; 2011. doi: 10.4061/2011/954757.

  17. Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev 2008; 24 (Suppl 1): S19–S24.

    Article  CAS  Google Scholar 

  18. American Diabetes Association. An up-to-date summary of the diagnosis and treatment of diabetes. Diabetes Care 2012; 35 (Suppl 1): 64–70.

    Article  Google Scholar 

  19. Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27: 2540–2553.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cairo University, 26, Street 18 from street 9, Mokattam, Cairo, Egypt

    Mary N. Rizk MD

  2. Department of Clinical Pathology, Egypt

    Ashraf I. Ameen

Authors
  1. Mary N. Rizk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashraf I. Ameen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary N. Rizk MD.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rizk, M.N., Ameen, A.I. Comorbidities associated with Egyptian diabetic foot disease subtypes. Egypt J Intern Med 25, 154–158 (2013). https://doi.org/10.7123/01.EJIM.0000432184.51306.20

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.7123/01.EJIM.0000432184.51306.20

Keywords